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Inhibition of Osteoclastogenesis 
and Bone Resorption in vitro 
and in vivo by a prenylflavonoid 
xanthohumol from hops
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Chunbing Zheng1, Xiushan Wu2, Jian Luo1 & Mingyao Liu1,3
Excessive RANKL signaling leads to superfluous osteoclast formation and bone resorption, is 
widespread in the pathologic bone loss and destruction. Therefore, targeting RANKL or its signaling 
pathway has been a promising and successful strategy for this osteoclast-related diseases. In this 
study, we examined the effects of xanthohumol (XN), an abundant prenylflavonoid from hops plant, 
on osteoclastogenesis, osteoclast resorption, and RANKL-induced signaling pathway using both in 
vitro and in vivo assay systems. In mouse and human, XN inhibited osteoclast differentiation and 
osteoclast formation at the early stage. Furthermore, XN inhibited osteoclast actin-ring formation 
and bone resorption in a dose-dependent manner. In ovariectomized-induced bone loss mouse 
model and RANKL-injection-induced bone resorption model, we found that administration of XN 
markedly inhibited bone loss and resorption by suppressing osteoclast activity. At the molecular 
level, XN disrupted the association of RANK and TRAF6, resulted in the inhibition of NF-κB and Ca2+/
NFATc1 signaling pathway during osteoclastogenesis. As a results, XN suppressed the expression 
of osteoclastogenesis-related marker genes, including CtsK, Nfatc1, Trap, Ctr. Therefore, our data 
demonstrated that XN inhibits osteoclastogenesis and bone resorption through RANK/TRAF6 
signaling pathways. XN could be a promising drug candidate in the treatment of osteoclast-related 
diseases such as postmenopausal osteoporosis.
Osteoclast are the only cells for bone-resorbing in mammals1. Many pathological bone diseases, includ-
ing postmenopausal osteoporosis, periodontitis, rheumatoid arthritis, lytic bone metastasis, and Paget’s 
disease, are characterized by progressive and excessive bone resorption2. Therefore, identification of 
agents to block osteoclast differentiation and resorption are the common and successful strategy for the 
development of therapeutic drugs for the osteoclast-related diseases3. However, the drugs for the diseases 
are far from ideal. For example, the most widely used anti-osteolytic treatment agent bisphosphonates, 
which inhibit osteoclast resorption by inducing osteoclast apoptosis, are poorly absorbed and can cause 
damage to the gastrointestinal tract4. Denosumab, a humanized monoclonal antibody to RANKL that 
inhibits osteoclast differentiation, can cause joint and muscle pain in the arms or legs and increase the 
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rates of infections5. Estrogen-replacement therapy, often treated for postmenopausal women, has been 
proven to increase the risk for uterine and breast cancer, blood clots, and heart attack, and its use has 
been prohibited for long-term treatment6. Therefore, there is considerable scientific and public interest 
in finding alternative agents and treatments for the osteoclast related diseases.
Osteoclasts are unique, multinucleated giant cells, which originate from hematopoietic cells. Osteoclast 
differentiation is dependent on two cytokines, a tumor necrosis factor (TNF) family cytokine, receptor 
activator of nuclear factor-κ B (NF-κ B) ligand (RANKL), and macrophage-colony stimulating factor 
(M-CSF)7–9. M-CSF can stimulate monocyte proliferation and supports its survival8. RANKL, which 
secreted from mesenchymal stem cell and osteoblasts, stimulates monocyte differentiation into osteo-
clasts7,9. The interaction of RANKL with its receptor RANK results in a cascade of intracellular events 
including nuclear factor kappa-light chain enhancer of activated B cells (NF-κ B), mitogen-activated pro-
tein kinases (MAPKs), ionic calcium, and calcium/calmodulin-dependent kinase by recruiting the adap-
tor signal protein TNF receptor associated factor (TRAF6)10. As a result, a number of osteoclast-related 
marker gene, including tartrateresistant acid phosphatase (Trap), calcitonin receptor (Ctr), cathepsin K 
(Ctsk), and nuclear factor of activated T cells (Nfatc1), are upregulated.
Hops (Humulus lupulus L.) are world-widely used raw material in brewing industry, especially for 
brewing beer. XN is the most abundant prenylflavonoid from hops plant, with a content of 0.1–1% (dry 
weight)11. This compound has attracted much interest due to its proven pharmacologic safety12 and 
its multiple bioactivities, including anti-cancer13, anti-diabetes14, anti-inflammatory11, anti-bacteria and 
parasite11, and hepatic protection11. Therefore, improved brewing technology to produces beer with high 
XN content has been established in the commercial industry11.
Recently, it has been reported that XN can inhibit osteoclast-related genes expression in mouse oste-
oclast cell line RAW264.7 cells15, and stimulate osteoblast differentiation in mouse osteoblast MC3T3-E1 
cells16. However, the precise molecular mechanism of anti-osteoclastogenesis of XN remains unknown, 
and the effect of XN on pathological bone loss and bone destruction in vivo has not yet been well defined. 
In the present study, using multiple in vitro osteoclast differentiation and bone resorption approaches, we 
demonstrated that XN suppressed RANKL-induced osteoclast formation and function within non-growth 
inhibitory concentrations. Moreover, we found that XN has inhibitory effects in two osteoclast-related 
animal models, the ovariectomy-induced bone loss mouse model and RANKL-injection-induced bone 
resorption model. Furthermore, XN abrogated the binding between RANK and TRAF6, which leading 
to the inhibition of NF-κ B and Ca2+/NFATc1 signaling pathway during osteoclastogenesis. As a result, 
XN suppressed the expression of osteoclastogenesis-related marker genes. Therefore, our data demon-
strate that XN suppresses osteoclastogenesis and osteoporosis in vitro and in vivo through RANK/TRAF6 
signaling pathways.
Materials and Methods
Regents and antibodies. Xanthohumol (XN), TRIS, Glycine, NaCl, sodium dodecyl sulfate (SDS), 
and bovine serum albumin (BSA) was obtained from Sigma (St Louis, MO, USA). RAW264.7 cells were 
the kind gift from Dr Bryant G Darnay (The University of Texas MD Anderson Cancer Center, TX, 
USA). Penicillin, streptomycin, a-MEM, and fetal bovine serum (FBS) were obtained from Invitrogen 
(Calbard, CA, USA). NFATc1 antibody is brought from Santa Cruz Biotechnology. All of the other anti-
bodies were bought from Cell Signaling Technology. Bacteria-derived recombinant mouse RANKL (462-
TEC) and M-CSF (416-ML) were from R&D Systems.
Proliferation assay with SRB method. The proliferation effect of XN was determined by SRB 
method as previously described17. The sulforhodamine B (SRB) method is used for cell proliferation 
and density determination, based on the measurement of cellular protein content17. Briefly, the cells 
(RAW264.7, BMMs and human monocyte cells) were treated with various concentration of XN. After 
4 days, all the cells are fixed by the gentle addition of 50 μ l of cold 50% TCA (final concentration, 10% 
TCA) and incubated for 60 minutes at 4 °C. The supernatant is discarded, and the plates are washed five 
times with tap water and air dried. Sulforhodamine B (SRB) solution (100 μ l) at 0.4% in 1% acetic acid 
is added to each well, and plates are incubated for 10 minutes at room temperature. Unconjugated SRB 
is washed by 1% acetic acid and then the conjugated SRB is dissolve in 10 mM Tris. Absorbance was 
measured with a Spectra MAX microplate reader (Molecular Devices).
BMMs isolation and in vitro osteoclast differentiation assay. For mouse primary cell culture, 
bone marrow cells isolated from mice were cultured as described previously18,19. Briefly, Bone marrow 
cells were isolated from flushing the femurs and tibias of 6- to 8-week-old C57BL/6 mice. To generate 
BMMs, the cells were cultured in α -MEM with 10% FBS containing 20 ng/ml M-CSF. To generate osteo-
clasts, the BMMs were seeded into 96-well plates and incubated with M-SCF (20 ng/ml) 2–3 days before 
stimulation with RANKL (30 ng/ml). After 6 or 4 days, cells were fixed and stained for Tartrate-resistant 
acid phosphatase (TRAP) activity (Sigma). TRAP positive multinucleated cells with more than 5 nuclei 
were counted as osteoclasts. For human osteoclastogenesis assay, human peripheral blood mononuclear 
cells (PBMCs) were isolated from healthy donor by Ficoll gradient centrifugation (provide by Shanghai 
Blood Center). The culture medium consisting of alpha minimal essential medium (α -MEM) supple-
mented with 10% foetal bovine serum (FBS). For osteoclastogenesis, 5 × 105 PBMCs were seeded in a 
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96-well plate with 20 ng/ml human CSF1 (Sino Biological Inc, 11792-H08Y). After 36 hours, cells were 
stimulated with 50 ng/mL human RANKL (R&D, 6449-TEC) and 20 ng/mL human CSF1 for 8–9 days. 
Medium was changed every two day. Osteoclasts were fixed and stained using the TRAP staining kit 
(Sigma, 387A-1KT).
Actin ring-formation assays. The actin ring-formation assay was performed as described previ-
ously6,20. BMMs differentiated in 6 days with RANKL and various concentration of XN. When the oste-
oclast formed, the cells were fixed with 4% paraformaldehyde for 10 mins at 4oC and then stained with 
0.1% phalloidine. The images were obtained by laser scanning confocal microscopy (Leica).
Bone resorption assay. To observe the bone resorption in vitro, BMMs were cultured with M-CSF 
plus RANKL for 6 days with or without different concentration of XN, then the dentin slices were treated 
with 1N NH4OH for 5 minutes and stained with 0.5% toluidine blue.
PCR amplification of reverse-transcribed RNA. For the semiquantitative RT-PCR anal-
ysis, total cellular RNA was extracted from cells using TRIzol reagent (Invitrogen). PCR prim-
ers are followed below: mouse TRAP, 5′ -GCTGGAAACCATGATCACCT-3′ (forward) and 
5′ -GAGTTGCCACACAGCATCAC-3′ (reverse); mouse Cathepsin K, 5′ -CTTCCAATACGTGCAG 
CAGA-3′ (forward) and 5′ -TCTTCAGGGCTTTCTCGTTC-3′ (reverse); mouse CTR, 5′ -TGCAGAC 
AACTCTTGGTTGG-3′ (forward) and 5′ -TCGGTTTCTTCTCCTCTGGA-3′ (reverse); mouse NFATc1, 
5′ -TGGAGAAGCAGAGCACAGAC-3′ (forward) and 5′ -GCGGAAA- GGTGGTATCTCAA -3′ (reverse); 
mouse β -actin 5′ -GGCTGTATTCCCCTCCATCG-3′ (forward) and 5′ -CCAGTTGGTAACAATGCC 
ATGT -3′ (reverse).
Intracellular Calcium imaging. To detect whether XN can inhibit calcium signaling in osteoclast, we 
performed a calcium imaging assay as previously described20. Briefly, All of the BMMs were incubated 
with M-CSF (20 ng/ml) in the intracellular calcium imaging experiment. The M-CSF incubated BMMs 
were pretreated with or without XN (5 uM) for 24 hours, and then incubated with or without RANKL 
(30 ng/ml) for another 60 hours. After loading with fura-2-acetomethoxy ester (Beyotime) (2 mM) for an 
additional 60 minutes in the dark at 37 °C, the cells were imaged at 340- and 380-nm excitation to detect 
intracellular free calcium (Olympus IX71 and LAMBDA DG-4) and recorded by In Vivo software and 
analyzed by Image-Pro Analyzer 6.2 software (Media Cybernetics). Therefore, the cells in Blank group 
only have M-CSF treatment, the cells in RANKL group have M-CSF and RANKL stimulation, while the 
cells in RANKL + XN group have M-CSF, RANKL, and XN treatment.
Luciferase reporter gene assay. RAW264.7 cells were then transfected with NF-κ B -luciferase plas-
mid and FUGENE reagent (Roche) in 5% serum media for 48 hours and then seeded in a 24-well, treated 
with RANKL and XN for another 24 hrs. Luciferase activity measured using a luciferase assay kit and a 
microplate luminometer.
Co-Imunoprecipitation assay. The coimunoprecipitation assay were performed as previously 
described21,22. Briefly, the RAW264.7 cells were seed in a 6-cm dish and pretreat with indicated concen-
tration of XN for 4 hours and then the cells were incubated with RANKL (30 ng/ml) for 20 minutes. The 
cells lysate supernatant were added with the RANK or TRAF6 antibody. After incubated with the protein 
A or G agarose beads (Thermo), the immunoprecipitated protein were subjected to Western blot using 
TRAF6 or RANK antibody.
Chromatin immunoprecipitation (CHIP) assay. The coimunoprecipitation assay were carried out 
as previously described23. Briefly, RAW264.7 cells were plated in 10-cm dish and treated with 30 ng/ml 
RANKL for 48 hours and then cross-linked with 1% formaldehyde for 10 min at room temperature 
before harvest. After sonicated, the sample was pre-cleared with Protein G Agarose/Salmon Sperm DNA 
(Millipore) at 4 °C for 1 h with rotation, and 1% of the pre-cleared chromatin was set aside as the input 
control. Immunoprecipitation was carried out with 5 μ g of antibody overnight at 4 °C against NFATc1 or 
Rabbit IgG (Santa Cruz Biotechnology). Immune complexes were pulled down and subjected to quan-
titative real-time PCR. Results were normalized to the input control. Primer for amplifing the NFATc1 
binding regions of the mouse cathepsin K promoter are 5′ -CCCCCAAAGTCAGTCAGATG-3 and 
5′ -GGTAAGGATTGCGGAAGTCA-3′ .
In vivo animal model. For the ovariectomy (OVX) animal study, Female 8-week-old C57/BL6 mice 
were performed ovariectomy or sham-operation. After four weeks, the OVX mice were random divided 
into two groups: OVX mice treated with vehicle group and OVX mice treated with XN group (n = 6). 
The mice were injected intraperitoneally with 10 mg/kg XN or vehicle control for another five weeks 
every day. Then, all the mice were euthanized with excess amounts of anesthetic. Bone histomorphom-
etry was analyzed on lumbar vertebrae as described previously6. For the RANKL-injection bone resorp-
tion model, RANKL/vehicle and RANKL/XN were injected into the calvaria of 6-week-old C57BL/6 
male mice (n = 6) every day for two weeks. The concentration of RANKL is 1 mg/kg and XN is 10 mg/kg. 
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At 15 days after the first injection, the mice were sacrificed and calvaria were collected. Mouse calvaria 
were collected for TRAP staining or section for TRAP staining (Sigma). All animal experiment pro-
cedures were approved by the Animal Care and Use Committee of the East China Normal University 
according to the animal standards of care of the National Institutes of Health.
Statistical analysis. All experimental data are presented as the mean SEM. Statistical significance 
was determined by the Mann-Whitney U test and Student’s t test. Significance was considered at p < 0.01.
Results
XN suppresses human and mouse osteoclast differentiation within non-growth inhibitory 
concentration. In order to determine the effect of XN on osteoclastogenesis, we employed three 
standard in vitro osteoclast differentiation models, mouse BMMs with RANKL and M-CSF stimula-
tion model, RAW264.7 cells with RANKL stimulation model, and human PBMC cells with RANKL 
and M-CSF stimulation model. As shown in Fig. 1A–C, TRAP positive multinucleated osteoclasts were 
formed in response to RANKL treatment. However, administration of XN reduced osteoclast differenti-
ation in a dose-dependent manner in all of the three cell models. The half maximal inhibitory concen-
tration (IC50) value of mouse osteoclast is about 1 μ M, while the IC50 value of human is between 0.25 
and 0.5 μ M.
To determine at which stage XN blocked osteoclastogenesis, XN was added to osteoclast differentia-
tion cultures beginning on days 0 to day 3 for RAW264.7 cells (Fig. 1D). Our results demonstrate that 
XN inhibited osteoclastogenesis maximally when added from the beginning with RANKL stimulation 
(Fig. 1D). The exposure of precursor cells to XN at later stages (more than 2 days) was much less effective 
in the blockage of osteoclastogenesis. Therefore, our data indicate that XN can suppress RANKL-induced 
osteoclastogenesis at the early stage and the differentiation process cannot be reversed.
To investigate whether the anti-osteoclastogenesis effect of XN is due to the potential toxicity of this 
compound, we further examined the cytotoxicity of XN by SRB assay on osteoclast cells (Fig. 1E,F). Our 
results showed that no significant cytotoxicity of XN was observed at the concentrations used, suggesting 
that the effects of XN on osteoclastogenesis are not mediated by the toxicity of the compound on cell 
viability.
XN blocks RANKL-induced actin-ring formation and bone-resorption activity in vitro. To fur-
ther examine the effects of XN on osteoclastogenesis, we examined whether XN affected RANKL-induced 
osteoclast function by bone resorption assays. Firstly, we tested whether XN could affect the actin-ring 
formation, which is a prerequisite for osteoclast bone resorption and is the most obvious character of 
mature osteoclast during osteoclastogenesis6,18. In the presence of RANKL exposure, BMMs can differen-
tiate into mature osteoclasts and form distinct actin-ring structures (Fig. 2A, left). However, XN signifi-
cantly reduced the size and the number of actin-ring structures in a dose-dependent manner, suggesting 
that XN suppressed the formation of actin-rings by matured osteoclasts.
To further explore whether XN inhibited bone-resorption ability of osteoclast in vitro, we performed 
the pit formation assays using BMMs cells as previously described20. As shown in Fig.  2B, osteoclasts 
caused bone-resorption and pit formation in the present of RANKL (Fig. 2B, left). Addition of XN signif-
icantly reduced the density of pits on the surface of dentin slices in a concentration-dependent manner 
(Fig. 2B). These results suggested that XN suppressed RANKL-induced bone resorption activity.
XN inhibits ovariectomy-induced bone loss by inhibiting osteoclast activity. To further 
test the possible efficacy in the treatment of pathological bone loss, we examined the effect of XN in 
post-ovariectomy osteoporosis using a therapeutic experimental protocol. Administration of XN started 
four weeks after ovariectomy (OVX) and treated for five weeks (Fig.  3A). Histomorphometric analysis 
of lumbar vertebrae showed that the trabecular bone volume (BV/TV) and trabecular number (Tb.N) 
were significantly increased in XN treated mice compared to vehicle-treated OVX mice, while trabec-
ular separation (Tb.Sp) was decreased relative to vehicle-treated OVX mice (Fig. 3B, right), suggesting 
that treatment of XN significantly inhibited the ovariectomy-induced bone loss. To explore whether XN 
suppressed bone loss through the inhibition of osteoclastogenic activity in vivo, we performed TRAP 
staining on the calvaria bone and quantified the TRAP positive area by software. Our data showed that 
treatment of OVX mice by XN dramatically decreased the OVX-induced osteoclast activity (Fig. 3C,D), 
indicating that XN could inhibit ovariectomy-induced osteoclast activity in vivo. Moreover, XN had little 
effect on body weight at the concentrations tested (Fig. 3E), suggesting little toxicity of XN at the tested 
doses in vivo.
XN abrogates RANKL-injection-induced bone resorption of osteoclast in vivo. To fur-
ther confirm the observation that XN inhibits bone resorption of osteoclast in vivo, we employed the 
extensively used RANKL-injection-induced bone resorption mouse model2,12. Our results showed that 
RANKL-injection dramatically induced the activity of osteoclast (Fig.  4A, middle), however adminis-
tration of XN strikingly suppressed the RANKL-injection-induced osteoclast activity (Fig.  4A, right). 
Histomorphometric analysis (RANKL + XN versus RANKL mice) indicated that XN inhibited the 
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Figure 1. XN suppresses human and mouse osteoclast differentiation. (A) The effect of xanthohumol 
(XN) on mouse BMMs differentiation. BMMs were incubated with M-CSF (20 ng/ml) and RANKL (30 ng/ml),  
followed by addition of different concentrations of XN for 6 days. The cells were stained for TRAP assay 
and photographed (× 40; left). The numbers of TRAP positive multinucleated (> 5 nuclei) osteoclasts 
were counted (right). (B) The effect of XN on RAW264.7 cell differentiation. RAW264.7 cells were treated 
with RANKL (30 ng/ml) and different doses of XN for 3 days. The cells were stained for TRAP assay 
and photographed (× 40; left) and the numbers of TRAP positive multinucleated (> 3 nuclei) osteoclasts 
were counted (right). (C) The effect of XN on human PBMC differentiation. PBMCs (5 × 105 cells) were 
stimulated with hRANKL (50 ng/mL) and hCSF1 (20 ng/mL) for 8–9 days. The cells were stained for 
TRAP assay and photographed (× 40; left) and the numbers of TRAP positive multinucleated (> 3 nuclei) 
osteoclasts were counted (right). (D) XN inhibits RANKL-induced osteoclast differentiation at the early 
stage. Osteoclast precursor BMMs were cultured with M-CSF and RANKL for differentiation into mature 
osteoclasts in 6 days. XN (5 μ M) were added at indicated time (day). The cells were fixed and stained for 
TRAP activity. (E) The effect of XN on cell viability in BMMs and RAW264.7 cells. BMMs or RAW264.7 
cells were treated with different concentrations of XN for 5 days, and the cell viability was measured by SRB 
assay. (F) The effect of XN on cell viability in human PBMC cells. Human PBMC cells were incubated with 
hCSF1 (20 ng/mL) and different concentrations of XN for 4 days. The cell viability was measured by SRB 
assay. Column, means of experiments performed in triplicate; bar, SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
N.S., no significant.
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Figure 2. XN inhibits RANKL-induced actin-ring formation and bone resorption. (A) The effect of XN 
on actin-ring formation of osteoclast. Mouse BMMs were incubated with RANKL (30 ng/ml) in the presence 
of M-CSF (20 ng/ml), followed by treatment with indicated doses of XN. Cells were fixed and stained for 
F-actin (top). Osteoclasts with actin-rings were counted (bottom). (B) The effect of XN on pits formation 
of osteoclast. Mouse BMMs were cultured with M-CSF (20 ng/ml) and RANKL (30 ng/ml) for 6 days with 
or without indicated doses of XN. The cells were washed and the resorption pits were stained with Mayer’s 
hematoxylin and photographed (top, original magnification, × 40). The numbers of pits were analyzed with 
Image-Pro software (bottom). Column, means of experiments performed in triplicate; bar, SD.
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RANKL-injection-induced bone resorption in vivo, including the osteoclast surface/bone surface (Oc.S/BS), 
eroded surface/bone surface (ES/BS), and osteoclast number/bone perimeter (N.Oc/B.Pm) (Fig. 4B).
XN inhibits RANKL-induced Ca2+/NFATc1 signaling pathway. RANKL-induced Ca2+/
NFATc1 signaling activation is among the very early molecular events in osteoclastogenesis6. Our 
observations indicated that XN inhibited RANKL-induced osteoclast differentiation at an early stage. 
Figure 3. XN inhibits ovariectomy-induced bone loss by inhibiting osteoclast activity in vivo. Four 
weeks after ovariectomy or sham-operation, mice were divided into three groups: sham-operated mice 
(sham), ovariectomized mice treated with vehicle (OVX) and OVX mice treated with XN (OVX + XN) (10 mg/kg, 
n = 6) for another five weeks. The treated mice were intraperitoneally (i.p.) injected with XN every days. 
Then, all the mice were euthanized for bone histomorphometry. (A,B) Histomorphometric analysis 
of lumbar vertebrae from sham, OVX, OVX + XN mice. Bone value/total value (BV/TV), trabecular 
space (Tb.Sp), and trabecular number (Tb.N) were analyzed as described in Materials and Methods. 
n = 6. (C,D) TRAP staining of the whole calvaria. The osteoclast area were analyzyed by OsteoMeasure 
Analysis system as described in Materials and Methods (D). (E) Effect of XN on mouse body weight at the 
concentrations tested. *p < 0.05, **p < 0.01, ***p < 0.001.
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Therefore, we employed three separate approaches to investigate whether XN inhibits RANKL-induced 
Ca2+/NFATc1 signaling pathway. First, using calcium imaging assay, we examined whether XN suppressed 
RANKL-induced Ca2+ oscillations. Our results showed that XN at 5 μ M completely diminished the ampli-
tude and frequency of Ca2+ oscillations induced by RANKL (Fig.  5A). Second, using NFAT-luciferase 
reporter gene assay, we found that the activity of NFAT, which is the downstream transcription factor 
of Ca2+ oscillation and the master regulator of osteoclastogenesis, was dose-dependently suppressed 
by XN in response to RANKL stimulation (Fig. 5B). Finally, using ChIP assay, XN concentration- and 
time-dependently suppressed the recruitment of NFATc1 on Ctsk promoter. To further confirm that 
XN inhibited osteoclast differentiation by suppressing RANKL-induced NFATc1 activity, we assessed 
whether overexpression of NFATc1 could rescue the XN-induced suppression of osteoclast differentia-
tion. Our results showed that XN inhibited osteoclast formation in control RAW264.7 cells, but had little 
inhibitory effect on osteoclastogenesis in NFATc1-overexpressed cells (Fig. 5E), suggesting that NFATc1 
prevented XN induced inhibition of osteoclastogenesis. All of the results demonstrate that XN suppresses 
osteoclast formation by inhibiting Ca2+/NFATc1 signaling pathway.
XN inhibits RANKL-induced NF-κB signaling pathway but not MAPK/AP-1 signal-
ing. RANKL-induced NF-κ B signaling pathway is another essential early molecular event during osteo-
clastogenesis24,25. Therefore, we next examined whether XN had any inhibitory effect on RANKL-induced 
NF-κ B signaling pathway. Using Western blot assay, we verified that XN inhibited the degradation of 
Figure 4. XN prevents RANKL-injection-induced osteoclast activity. RANKL/vehicle and RANKL/XN 
were injected into the calvaria of 6-week-old male mice every day, respectively (n = 6). After 15 days, the 
mice were sacrificed and calvaria were stained by TRAP staining and sectioned. (A) Representative TRAP 
stained whole calvaria (top) and calvarial section (bottom) from normal mice, RANKL/vehicle injected 
mice (RANKL) and RANKL/XN injected mice (RANKL + XN). (B) Eroded surface/bone surface (ES/BS); 
osteoclast surface/bone surface (Oc.S/BS); osteoclast number/bone perimeter (N.Oc/B.Pm) were analyzed by 
OsteoMeasure Analysis system as described in Materials and Methods.
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Figure 5. XN blocks RANKL-induced Ca2+/NFATc1 signaling pathway. (A) The effect of XN on RANKL-
induced Ca2+ oscillation. The M-CSF incubated BMMs were pretreated with or without XN (5 uM) for 24 hours, 
and then incubated with or without RANKL (30 ng/ml) for another 60 hours. The Ca2+ oscillation was analyzed 
as described in Materials and Methods. (B) The effect of XN on RANKL-induced activity of NFAT. RAW264.7 
cells were cotransfected with NFAT-luciferase reporter gene and Renilla gene. After 36 hours, the cells were 
treated with RANKL and indicated concentrations of XN for another 24 hours. Cell extracts were collected and 
luciferase activity was measured as described in Materials and Methods. Results are expressed as fold activity over 
the activity of the control. (C,D) The effect of XN on NFATc1 binding to Cathepsin K (Ctsk) promoter region 
by Chromatin immunoprecipitation (ChIP) assays. BMMs incubated with RANKL (30 ng/ml) were treated with 
or without XN for indicated time (C). Or BMMs incubated with RANKL (30 ng/ml) were treated with indicated 
concentration of XN for 48 hours (D). The Chromatin DNA were immunoprecipitated with control IgG or the 
anti-NFATc1 antibody and subjected to quantitative real-time PCR with primers specific for NFATc1-binding sites. 
(E) NFATc1 prevents the inhibitory effect of XN in RANKL-induced osteoclast differentiation. RAW264.7 cells 
were transfected with NFATc1 or vector control plasmids, and then incubated with or without XN (5 μ M) in the 
presence of RANKL (30 ng/ml). After 4 days, the cells were fixed and stained for TRAP activity (left). Original 
magnification, × 40. The numbers of TRAP positive multinucleated (> 3 nuclei) osteoclasts were counted (right). 
Column, means of three experiments conducted in triplicate; bar, SD. ***P < 0.001.
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Figure 6. XN suppresses RANKL-induced NF-κB signaling pathway, but has little effect on MAPK/
AP-1 signaling. (A) The effect of XN on RANKL-induced Iκ Bα degradation and p65 phorsphorylation. 
RAW264.7 cells were pretreated with XN (5 μ M) for 3 hours, and then stimulated with RANKL  
(30 ng/ml) for indicated time. The degradation of Iκ Bα and the phosphorylation of p65 were tested by 
Western blot analysis (left). The Western blot were performed in triplicate. The Iκ Bα protein level (with 
β -actin for normalization) were quantified by Quantity One software (right). (B) The effect of XN on 
RANKL-induced p65 nuclear translocation. RAW264.7 cells were pretreated with different doses of XN 
for 3 hours, and then stimulated with RANKL for 20 minutes. Cell Nuclear Extracts (NE) and Cytoplasmic 
Extract (CE) were collected and subjected to Western blot analysis with the indicated antibodies. 
(C) The effect of XN on RANKL-induced activity of NF-κ B. RAW264.7 cells were co-transfected with 
NF-κ B-luciferase reporter gene and Renilla gene. After 48 hours, the cells were treated with RANKL and 
indicated concentrations of XN for another 24 hours. Cell extracts were collected and luciferase activity 
was measured. (D) NF-κ B (p65) prevents the inhibitory effect of XN in RANKL-induced osteoclast 
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differentiation. RAW264.7 cells were transfected with p65 or control plasmids, and then incubated with 
or without XN (5 μ M) in the presence of RANKL (30 ng/ml). After 4 days, the cells were stained for 
TRAP activity and the numbers of osteoclasts were counted. (E) XN has little effect on RANKL-induced 
phosphorylation of MAPKs. BMMs were cultured in the presence of XN (5 μ M) for 4 hours, and then 
RANKL was stimulated at the indicated time points. Cell lysates were extracted for Western blot analysis 
with indicated antibodies. (F) XN has little effect on the activity of AP-1 induced by RANKL. RAW264.7 
cells were co-transfected with AP-1-luciferase reporter gene and Renilla gene. After 48 hours, the cells were 
treated with RANKL and indicated concentrations of XN for another 24 hours. Cell extracts were collected 
and luciferase activity was measured. Column, means of experiments conducted in triplicate; bar, SD. 
*p < 0.05, **p < 0.01, ***p < 0.001.
Iκ Bα and the phosphorylation of NF-κ B/p65 induced by RANKL (Fig.  6A). Furthermore, XN sup-
pressed RANKL-stimulated nuclear translocation of NF-κ B/p65 in a dose-dependent manner (Fig. 6B). 
Similar results were obtained by the luciferase reporter gene assay that XN concentration-dependently 
suppressed RANKL-induced NF-κ B activity (Fig. 6C). As expected, NF-κ B/p65 prevents the inhibitory 
effect of XN in RANKL-induced osteoclastogenesis (Fig. 6D). Together, all of the data indicate a role of 
XN in the modulation of NF-κ B signaling pathways.
Besides the activation of NFAT and NF-κ B signaling pathway, activation of the MAPK/AP-1 path-
way plays a pivotal role in osteoclastogenesis26,27. Interestingly, our data showed that RANKL-induced 
phosphorylation of p38, JNK1/2, ERK1/2 were not affected with XN treatment (Fig. 6E). Furthermore, 
XN has little effect on AP-1-lucifearse reporter gene activity within the osteoclastogenesis inhibitory 
concentration (Fig. 6F), suggesting that XN had little effect on MAPK/AP-1 signaling.
XN abrogates RANKL-induced association of RANK and TRAF6. Since the NF-κ B and 
Ca2+/NFATc1 pathways share the same upstream molecule, TRAF6, which is associated with RANK 
when activated by RANKL28, we then examined the possible effect of XN in the binding between RANK 
and TRAF6. In the endogenous coimmunoprecipitation assay, XN suppressed RANKL-induced associ-
ation of RANK and TRAF6 in a dose-dependent manner when immunoprecipitated with antibody to 
RANK and blotted with anti-TRAF6 (Fig. 7A). On the other end, XN also inhibited the binding when 
immunoprecipitated with antibody to TRAF6 and blotted with anti-RANK (Fig. 7B). All of the results 
suggested that XN could dissociate the signal complex RANK and TRAF6.
XN suppresses RANKL-induced osteoclastogenesis-related marker gene expression. To 
further confirm the role of XN in osteoclast differentiation, we examined the effects of XN on the 
osteoclastogenesis-related marker gene expression, including CtsK, Nfatc1, Trap, and calcitonin receptor 
(Ctr), all of which are downstream target genes of NF-κ B and Ca2+ /NFATc1 pathways29–31. Our data 
showed that XN strikingly suppressed the expression of all target genes, including CtsK, Nfatc1, Trap 
and Ctr in a time-dependent manner during RANKL-induced osteoclastogenesis (Fig. 7C). Thus, XN is 
a novel agent to suppress osteoclast differentiation and function.
Discussion
Hyper-activation of RANKL signaling results in enhanced osteoclast formation and bone resorption, 
which is common in the pathologic bone destruction, including rheumatoid arthritis, bone tumor and 
bone metastasis, periodontitis. Therefore, regression of RANL signaling is a proven therapeutic method 
to the treatment of osteoclast-related diseases6. In this report, we demonstrated that XN could inhibit 
osteoclast differentiation and bone resorption in a dose-dependent manner. In two animal model, XN 
suppressed bone loss and bone destruction through the suppression of osteoclast activity. Our data 
also found that XN disrupted the association of RANK and TRAF6, which leaded to the suppression 
of NF-κ B and Ca2+/NFATc1 signaling pathway during osteoclastogenesis. As a result, XN blocked the 
expression of osteoclastogenesis-related marker genes.
Bone is constantly regenerated through continuous formation by osteoblasts and resorption by 
osteoclasts, which is termed bone remodeling32. Previous report demonstrate that XN can stimulate 
osteoblast differentiation, induce the activity of alkaline phosphatase (ALP), upregulates the osteoblast 
marker gene Runx2 expression in mouse osteoblast MC3T3-E1 cells16. Furthermore, inhibition of p38 
and Erk abrogates the XN-induced Runx2 expression during osteoblast differentiation16, suggesting XN 
might stimulate osteoblast differentiation by activating p38 and ERK signaling pathway. In our study, 
we demonstrated that XN inhibits osteoclastogenesis in vivo and in vitro. These results indicated that 
XN could be an attractive therapeutic agent for treating osteoporosis with dual roles in promoting bone 
formation and inhabiting bone resorption. Interesting, XN has little effect on MAPK signaling pathway 
in osteoclast, including the phosphorylation of p38, ERK and JNK, suggesting different molecular mech-
anisms for the effects of XN in bone formation and bone resorption.
It has been reported that RANK/TRAF6 complex is essential for the activation of NF-κ B, MAPKs 
and Ca2+ oscillation under RANKL stimulation33,34. Deficiency of Traf6 in mice exhibits bone pheno-
types similar to Rankl−/− and Rank−/− in which osteocalstogenesis is largely blocked and the downstream 
signaling pathways, including NF-κ B, MAPKs and Ca2+ oscillation, cannot be stimulated by RANKL33. 
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Figure 7. XN represses the association of RANK and TRAF6, and abrogates osteoclastogenesis-related 
gene expression. (A,B) XN suppressed the RANKL-induced binding of RANK and TRAF6. The RAW264.7 
cells were pretreated with indicated concentration of XN for 4 hours then stimulated with RANKL 
(30 ng/ml) for another 20 minutes. The cell lysate were harvest and immunoprecipitated with antibody to 
RANK and then blotted with anti-TRAF6 (A). Or the cell lysates were immunoprecipitated with antibody 
to TRAF6 and then blotted with anti-RANK (B). (C) XN inhibits the mRNA levels of NFATc1, cathepsin K 
(CtsK), CTR and TRAP induced by RANKL. Mouse BMMs were incubated with XN (5 μ M) and RANKL 
(30 ng/mg) for indicate day. Total RNA was collected and analyzed by Real time-PCR. Column, means of 
experiments performed in triplicate; bar, SD. **p < 0.01.
However, mutation assays showed that mutation of the membrane-proximal TRAF6 interaction domain 
in RANK results in completely inhibition of NF-κ B signaling, while the MAPK/AP-1 signaling is still 
possible33,35,36, suggesting that RANK-mediated downstream signaling is domain-dependent33. In our 
study, we found that XN inhibited RANKL-induced activation of NF-κ B and Ca2+/NFATc1 signaling 
pathway, but has little effect on MAPK/AP-1 pathway, and XN markedly abrogated the association of 
RANKL and TRAF6. It is reasonable to speculate that XN targeted the specific TRAF6 binding domain 
in RANK which is responsible for the activation of NF-κ B and Ca2+/NFATc1 signaling pathway, but not 
the MAPK/AP-1 pathway.
Previous studies have demonstrated that NFATc1 is a master regulator during osteoclastogenesis34. 
Activated NF-κ B can be recruited to the promoter of NFATc1 and regulates its expression34. Calcium sig-
naling leads to nuclear translocate and activate NFATc1 by the Ca2+/calmodulin-dependent phosphatase 
calcineurin34. Specially, NF-κ B and Ca2+oscillation are known to initially induce NFATc1 expression and 
activity at early stage during osteoclastogenesis. Our results indicate that XN suppresses RANKL-induced 
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osteoclastogenesis only at the early stage by inhibiting the binding of RANK and TRAF6, abrogating 
NF-κ B and Ca2+ oscillation signaling, and blocking NFATc1 expression and activity. Therefore, our data 
strongly suggest that XN inhibit osteoclastogenesis only at the early stage by modulating the RANK/
TRAF6 signaling.
Using ovariectomized mouse model and RANKL-injection-induced bone resorption model, our data 
demonstrate that XN is a promising anti-osteoclastogenesis agent with little toxicity in vivo. Many patho-
logical osteoclast-related bone diseases, including periodontitis, rheumatoid arthritis, lytic bone metas-
tasis, and Paget’s disease, are characterized by progressive and excessive osteoclastogenesis and bone 
resorption. It has been reported that XN also has effect on tumor and inflammation11. Therefore, further 
investigation will be necessary and interesting to examine the effect of XN on periodontitis, rheumatoid 
arthritis, lytic bone metastasis, and Paget’s disease.
In summary, our data demonstrate that XN can inhibit osteoclastogenesis in vitro and in vivo through 
suppressing RANK/TRAF6 interaction, and blocking NF-κ B and Ca2+/NFATc1 signaling pathway. All of 
the results suggest that XN is a potential therapeutic agent in the treatment of osteoclast-related diseases 
such as osteoporosis.
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